Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by BearDownAZon Sep 10, 2015 2:17pm
116 Views
Post# 24093440

RE:Does PoC have a good side?

RE:Does PoC have a good side?Prince, 

Regarding the BoM potential shorter timeline, this was based upon information put into the public record regarding the a) MACE event rates in the diabetic/low HDL population in the ASSURE/SUSTAIN analysis; b) the BETonMACE design of targeting to reach 250 MACE events; and c) the projected # of patients.

Anyone who has read my posts in their entirety knows that I am very critical of the information I use and when something is uncertain I will indicate that. For the above potential BETonMACE timeline, I always qualified my statements by indicating that none of us will know any trial details for certain until the trial is launched and the BETonMACE protocol is available to view. 

Forecasting a potential outcome based on available information at the time, while at the same time providing clear caveats, is not pumping in my book. That is critical analysis. You should try it sometime. And even now, we still don't have a clear picture of the real potential timelines because the trial hasn't started and the full protocol isn't released. So how can you be right? Get over yourself prince.

BDAZ

PoC wrote: ..you were pumping BoM done in 6 months and i called you on it...i was right and you was wrong and BTW i provided likely reasons why you were wrong (ps seems in part IMO 30% is now due to tighter MACE measures)"
Read more at https://www.stockhouse.com/companies/bullboard/t.rvx/resverlogix-corp#63LpoJ3pxtjGm6yb.99
Bullboard Posts